Skip to main content
Premium Trial:

Request an Annual Quote

David Byram

GeneNews announced that it has appointed David Byram as Chief Commercial Officer for its US lab, Innovative Diagnostics Laboratory (IDL). Byram will oversee all of the IDL customer's-facing activities, including sales, client relations, and commercial operations. Prior to joining IDL, Byram was VP, commercial and government affairs for Braeburn Pharmaceuticals. Prior to Braeburn, Byram held positions as senior VP, commercial affairs for Orexo AB/US, US director, public sector for Indivior, and senior director, strategic accounts and public affairs for Janssen Biotech. 

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.